The Science of MS Management:
The Role of Gender in MS Disease Progression and Treatment
Corey C. Ford, MD, PhD; Rhonda Voskul, MD |
CME/CE Released: 03/31/2014; Valid for credit through 03/31/2015
|
Faculty and Disclosures
|
Corey C. Ford, MD, PhDDr. Ford has disclosed the following financial relationships:Sources of Funding for Research: Biogen Idec, Elan, Genentech, Genzyme, Janssen, Novartis, Ono Pharmaceutical, Sanofi Aventis, Serono, and Teva CNS.Consulting Agreements: Biogen Idec, Novartis, and Teva CNS.
Rhonda Voskuhl, MDDr. Voskuhl has disclosed no relevant financial relationships.
ReviewerLaurie Scudder, DNP, NPLaurie Scudder has disclosed no relevant financial relationships.
Planners and ManagersThe following planners and managers have disclosed no relevant conflicts of interest: Joseph J. D’Onofrio, Frank Marino, Nancy Monson, Katherine Wandersee.
|
Target Audience |
This publication is targeted to neurologists and physicians who have an interest in treating multiple sclerosis (MS). |
Learning Objectives |
Upon completion of this educational activity, the participant should be able to:
|
Disclosure |
Disclosure of Non-endorsement of ProductsApproval does not imply endorsement by the CMSC or ACCME of any commercial products discussed in conjunction with an educational activity.Disclosure of Unlabeled UseThis CME activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC, Teva CNS, and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC, Teva CNS, or Delaware Media Group.DisclaimerParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities. |
Accreditation and Designation |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Consortium of Multiple Sclerosis Centers (CMSC) and the Delaware Media Group. The CMSC is accredited by the ACCME to provide continuing medical education for physicians.The CMSC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Release Date: March 31, 2014Credit for this program expires on March 31, 2015. |
Method of Participation |
Follow these steps to earn CME credit:
Code: CMSC-DELMED 2014/1 |
Privacy Policy and Confidentiality |
CMSC is committed to honoring the privacy of participants in educational activities. Our full privacy policy is available on our website at http://www.mscare.org/privacy.aspx |
Other Information |
Jointly sponsored by the Consortium of Multiple Sclerosis Centers and Delaware Media Group.This continuing education publication is supported by an educational grant from Teva CNS.For questions relating to CME, please contact the CMSC at (201) 487-1050 or email education@mscare.org. |
Hardware/Software Requirements |
The minimum requirements for viewing an on-line book is an active internet connection and Flash (free software from Adobe) version 10 or higher. |
Link to the Program |
~~~~~~~~~~~~~~~~~~~~
Keep CURRENT and up to date, with MS News and Information
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews